Matthew W. Foehr - 11 Nov 2021 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
President and COO
Signature
By: Charles S. Berkman For: Matthew W. Foehr
Issuer symbol
LGND
Transactions as of
11 Nov 2021
Net transactions value
-$1,471,437
Form type
4
Filing time
12 Nov 2021, 15:54:05 UTC
Previous filing
05 Aug 2021
Next filing
05 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $103,191 +1,028 +0.62% $100.38 166,525 11 Nov 2021 Direct
transaction LGND Common Stock Options Exercise $244,627 +11,160 +6.7% $21.92 177,685 11 Nov 2021 Direct
transaction LGND Common Stock Sale $1,819,255 -11,160 -6.3% $163.02 166,525 11 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -11,160 -100% $0.000000* 0 11 Nov 2021 Common Stock 11,160 $21.92 Direct F2
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -1,028 -4.1% $0.000000 24,348 11 Nov 2021 Common Stock 1,028 $100.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.41 to $166.38, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.
F3 Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/24/2017.